Barclays Appoints Amit Tyagi as a Managing Director in Healthcare Investment Banking
September 14 2021 - 4:20PM
Business Wire
Barclays announces the appointment of Amit Tyagi as a Managing
Director in Healthcare Investment Banking. Mr. Tyagi will be based
in New York, and will focus on the Tools and Diagnostics sector. He
will report to Rick Landgarten, Global Head of Healthcare &
Real Estate Groups at Barclays.
Mr. Tyagi joins Barclays with over 20 years of industry
experience, most recently as Head of Healthcare at Huatai
Securities. Prior to joining Huatai Securities in 2018, Mr. Tyagi
was Global Head of Medical Diagnostics and Life Sciences Tools at
UBS. Before joining UBS in 2008, he worked as a senior project
manager at Medline Industries. Mr. Tyagi has led the origination
and execution of a number of high-profile transactions during his
career. These include advising Genstar Capital on its acquisition
of Symmetry Medical’s OEM, advising Asahi Kasei on its acquisition
of Zoll Medical, advising Zonare Medical Systems on the company’s
sale to Mindray, and advising QuantaLife on its sale to
Bio-Rad.
“Amit is an outstanding addition to our Healthcare team, and his
extensive industry knowledge and transaction experience will
further strengthen our ability to provide a superior value
proposition to our clients,” said Rick Landgarten, Global Head of
Healthcare & Real Estate Groups. “Amit’s appointment is further
evidence of our commitment to investing in and operating a top-tier
Healthcare franchise.”
Barclays has performed lead roles in a number of recent
transactions of note in the Healthcare Banking space, including
serving as financial advisor to Thermo Fisher Scientific on their
pending $21bn acquisition of PPD, and acting as financial advisor
to Centene Corporation in the company’s $3.1bn acquisition of
Magellan Health, Inc. Barclays acted as financial advisor to
Kindred at Home on their sale to Humana, and served as financial
advisor to HMS on the company’s sale to Veritas Capital-backed
Gainwell Technologies for $3.4bn. In addition, Barclays has
performed key roles in several recent IPOs of note, including
serving as a senior active bookrunner on a $649mm IPO for Signify
Health, Inc., as an active bookrunner on a $924mm IPO for Bright
Health Group, Inc., and as an active bookrunner on a $1.3bn IPO for
GoodRx Holdings, Inc.
Barclays is a British universal bank. We are diversified by
business, by different types of customer and client, and geography.
Our businesses include consumer banking and payments operations
around the world, as well as a top-tier, full service, global
corporate and investment bank, all of which are supported by our
service company which provides technology, operations and
functional services across the Group. For further information about
Barclays, please visit our website www.barclays.com. Barclays
offers investment banking products and services in the US through
Barclays Capital Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210914006148/en/
Press: Andrew Smith +1 212 412 7521
andrew.x.smith@barclays.com
Barclays (NYSE:BCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Barclays (NYSE:BCS)
Historical Stock Chart
From Apr 2023 to Apr 2024